People who have Hodgkin's lymphoma or systemic anaplastic large cell lymphoma (ALCL) may benefit from chemotherapy treatment with Adcetris. This prescription drug is given through an intravenous (IV) infusion every three weeks, and is only recommended after other chemotherapy treatments have failed. Most people who receive it will develop some type of side effect, such as fatigue, nausea, and diarrhea.
What Is Adcetris?Adcetris™ (brentuximab vedotin) is a prescription medication approved to treat Hodgkin's lymphoma and a type of non-Hodgkin's lymphoma known as systemic anaplastic large cell lymphoma (ALCL). It is reserved for use after other treatments have failed.
How Does Adcetris Work?Adcetris is a combination of a drug and an antibody (a protein normally made by the immune system that recognizes and attaches to an antigen). The antibody portion of Adcetris attaches to CD30, an antigen found on the surface of some lymphoma cells. Once attached, Adcetris enters the cell and releases the drug portion. The drug portion of Adcetris binds to tubulin, an important protein found inside the cells, causing the cell to die.
Clinical EffectsAdcetris was studied in people with Hodgkin's lymphoma and systemic ALCL. In these studies, 73 percent of people with Hodgkin's lymphoma who were given the medication had at least a 50 percent reduction in the size of their lymphoma tumors. In the systemic ALCL studies, 86 percent of people given Adcetris had their tumors shrink by at least half.